This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Pfizer Dirección

Dirección controles de criterios 3/4

Información clave

Albert Bourla

Chief Executive Officer (CEO)

US$24.4m

Compensación total

Porcentaje del salario del CEO	6.9%
Permanencia del CEO	4.2yrs
Participación del CEO	0.007%
Permanencia media de la dirección	3.6yrs
Promedio de permanencia en la Junta Directiva	6.1yrs

Actualizaciones recientes de la dirección

No hay actualizaciones

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Albert Bourla en comparación con los beneficios de Pfizer?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2022	n/a	n/a	US$31b
Oct 02 2022	n/a	n/a	US$30b
Jul 03 2022	n/a	n/a	US$29b
Apr 03 2022	n/a	n/a	US$25b
Dec 31 2021	US$24m	US$2m	US$22b
Oct 03 2021	n/a	n/a	US$19b
Jul 04 2021	n/a	n/a	US$12b
Apr 04 2021	n/a	n/a	US$9b
Dec 31 2020	US$21m	US$2m	US$7b
Sep 27 2020	n/a	n/a	US$212m
Jun 28 2020	n/a	n/a	US$7b
Mar 29 2020	n/a	n/a	US$9b
Dec 31 2019	US$18m	US$2m	US$11b
Sep 29 2019	n/a	n/a	US$16b
Jun 30 2019	n/a	n/a	US$13b
Mar 31 2019	n/a	n/a	US$11b
Dec 31 2018	US$10m	US$1m	US$4b
Sep 30 2018	n/a	n/a	US$24b
Jul 01 2018	n/a	n/a	US$23b
Apr 01 2018	n/a	n/a	US$22b
Dec 31 2017	US$9m	US$1m	US$21b
Oct 01 2017	n/a	n/a	US$10b
Jul 02 2017	n/a	n/a	US$8b
Apr 02 2017	n/a	n/a	US$7b
Dec 31 2016	US$9m	US$1m	US$7b

Compensación vs. Mercado: Albert's total compensation ($USD24.35M) is above average for companies of similar size in the Swedish market ($USD2.50M).

Compensación vs. Ingresos: Albert's compensation has been consistent with company performance over the past year.

CEO

Albert Bourla (60 yo)

4.2yrs

Permanencia

US$24,353,219

Compensación

Dr. Albert Bourla, DVM, Ph.D. serves as the Chief Executive Officer of Pfizer Inc. since January 1, 2019 and has been its Executive Director since February 23, 2018. Dr. Bourla was Chief Operating Officer...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Albert Bourla	Chairman of the Board & CEO	4.2yrs	US$24.35m	0.0074% $ 176.1m
Mikael Dolsten	Chief Scientific Officer and President of Worldwide Research	4.2yrs	US$10.91m	sin datos
Douglas Lankler	Executive VP & General Counsel	9.3yrs	US$7.13m	0.0032% $ 77.1m
John Young	Advisor	1.6yrs	US$8.39m	0.0054% $ 129.2m
Angela Hwang	Chief Commercial Officer & President of Global Biopharmaceuticals Business	5.2yrs	US$9.03m	0.0011% $ 26.2m
David Denton	Chief Financial Officer & Executive VP	less than a year	sin datos	0.000020% $ 475.9k
Jennifer Damico	Senior VP	3yrs	sin datos	0.00019% $ 4.5m
Lidia Fonseca	Executive VP and Chief Digital & Technology Officer	4.2yrs	sin datos	0.00062% $ 14.8m
Christopher Stevo	Senior VP & Chief Investor Relations Officer	1.7yrs	sin datos	sin datos
Rady Johnson	Executive VP and Chief Compliance	9.3yrs	sin datos	0.0016% $ 37.6m
Andreas Panayiotou	Global Chief Marketing Officer	less than a year	sin datos	sin datos
Payal Becher	Chief People Experience Officer & Executive VP	2.8yrs	sin datos	0.00049% $ 11.7m

3.6yrs

Permanencia media

56.5yo

Promedio de edad

Equipo directivo experimentado: PFE's management team is considered experienced (3.6 years average tenure).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Albert Bourla	Chairman of the Board & CEO	5.1yrs	US$24.35m	0.0074% $ 176.1m
Shantanu Narayen	Lead Independent Director	9.5yrs	US$405.00k	sin datos
Ronald Blaylock	Independent Director	6.1yrs	US$345.00k	0.00023% $ 5.5m
Suzanne Nora Johnson	Independent Director	15.5yrs	US$365.00k	0.00018% $ 4.3m
James Smith	Independent Director	8.8yrs	US$365.00k	0.000060% $ 1.4m
Charles Hagel	Member of Emerging Markets Advisory Board	no data	sin datos	sin datos
Susan Hockfield	Independent Director	3yrs	US$339.35k	sin datos
Daniel Littman	Independent Director	5yrs	US$350.90k	sin datos
James Robert Quincey	Independent Director	3.1yrs	US$355.00k	sin datos
Scott Gottlieb	Independent Director	3.8yrs	US$365.00k	0.000070% $ 1.7m
Joseph Echevarria	Independent Director	7.8yrs	US$365.00k	sin datos
Helen Hobbs	Independent Director	11.3yrs	US$385.00k	sin datos

6.1yrs

Permanencia media

63.5yo

Promedio de edad

Junta con experiencia: PFE's board of directors are considered experienced (6.1 years average tenure).

This company listing is no longer active

Pfizer Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Recent updates

Pfizer Inc. and Valneva SE Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15

FDA Approves Pfizer Inc.'s Supplemental New Drug Application for CIBINQO

Full year 2022 earnings released: EPS: US$5.59 (vs US$4.00 in FY 2021)

Pfizer Inc. Provides Earnings Guidance for the Financial Year 2023

Upcoming dividend of US$0.41 per share

U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer's 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children

Pfizer Inc. Announces Positive Top-Line Results from Phase 3 Study of Hemophilia B Gene Therapy Candidate

Sosei Heptares' Partner Pfizer Progresses its Oral GLP-1 Receptor Agonist PF-07081532 into Phase 2 Clinical Trials for Treating Type 2 Diabetes and Obesity

Pfizer Inc. to Report Q4, 2022 Results on Jan 31, 2023

Pfizer Inc. Presents Updated Favorable Elranatamab Data from Pivotal Phase 2 MagnetisMM-3 Trial

Pfizer Inc. Declares an Increase in the Quarterly Cash Dividend on the Company's Common Stock for the First-Quarter 2023 Dividend, Payable March 3, 2023

Pfizer Inc Announces U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer's Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV Disease in Older Adults

BioNTech SE and Pfizer Inc. Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-adapted bivalent COVID-19 Vaccine in Children Under 5 years

Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults for Lyme Disease Vaccine Candidate

Arvinas, Inc. Announces Initial Results from Phase 2 Cohort Expansion Portion (VERITAC) of Phase 1/2 Study with ARV-471 Co-Developed with Pfizer Inc

Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages

Pfizer Inc. and BioNTech SE Advances Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T Cell Responses and Duration of Protection

Pfizer and Biontech Receive Positive Chmp Opinion for Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union

Pfizer Inc. and BioNTech SE Announces Updated Clinical Data for Omicron Ba.4/Ba.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine

Pfizer's Elranatamab Granted FDA Breakthrough Therapy Designation for Relapsed or Refractory Multiple Myeloma

Third quarter 2022 earnings released: EPS: US$1.54 (vs US$1.45 in 3Q 2021)

Pfizer Inc. Revises Earnings Guidance for the Fourth Quarter of 2022

Upcoming dividend of US$0.40 per share

Pfizer and Biontech Receive Positive CHMP Opinion for Comirnaty® in Children 6 Months to Less Than 5 Years in the European Union

Pfizer and BioNTech Announce Positive Early Data from Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age

Pfizer Inc. (NYSE:PFE) completed the acquisition of Global Blood Therapeutics, Inc. (NasdaqGS:GBT) from a group of shareholders.

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad